William Blair Has Negative Estimate for DVAX Q3 Earnings

Key Points

• Analysts at William Blair have reduced their Q3 2025 EPS forecast for Dynavax Technologies from $0.15 to $0.13, impacting investor expectations.
• The company reported Q2 earnings of $0.14 EPS, exceeding the consensus estimate of $0.12, with revenue of $95.44 million against expectations of $87.55 million.
• Dynavax Technologies' stock is currently rated as a "Moderate Buy" with an average target price of $24.33, despite recent downward adjustments and varying analyst opinions.

Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) - Analysts at William Blair dropped their Q3 2025 EPS estimates for shares of Dynavax Technologies in a report issued on Friday, August 8th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $0.13 per share for the quarter, down from their previous estimate of $0.15. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies' Q4 2025 earnings at $0.05 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.09 EPS, FY2026 earnings at $0.58 EPS and FY2028 earnings at $1.07 EPS.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group reduced their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday. Finally, JMP Securities lifted their price objective on shares of Dynavax Technologies from $31.00 to $32.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Stock Performance

Shares of DVAX traded up $0.21 during midday trading on Monday, reaching $10.79. The stock had a trading volume of 829,251 shares, compared to its average volume of 2,096,836. The firm has a market cap of $1.26 billion, a PE ratio of -23.51 and a beta of 1.09. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. The firm has a 50 day simple moving average of $10.53 and a 200-day simple moving average of $11.52. Dynavax Technologies has a one year low of $9.22 and a one year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The company had revenue of $95.44 million during the quarter, compared to the consensus estimate of $87.55 million.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its holdings in Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies in the 1st quarter valued at $30,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,304 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at $35,000. Finally, GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.